IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429 Volume 6, Issue 20, April 2026 Impact Factor: 8.2

Application of Artificial Intelligence in Detection, Diagnosis and Treatment of Cardiovascular Diseases – A Review

Miss Akanksha Kadam, Mr Narsing Upase, Miss Darshana Maheshan
Mr Sangmesh Hasargunde, Miss Kavita Sirgire
Shivlingeshwar College of Pharmacy, Almala
Department of Pharmacology
akukadam1792@gmail.com, upasenarsing333@gmail.com
maheshandarshana@gmail.com, sangmeshhasargunde@gmail.com, scop.pcol.sks@gmail.com

Abstract: *Artificial Intelligence (AI) has emerged as a transformative technology in cardiovascular medicine, enabling improved detection,diagnosis treatement of cardiovascular diseases (CVDs). AI techniques, including machine learning and deep learning, analyze large and complex datasets such as electrocardiograms (ECG), imaging, and electronic health records. These technologies enhance early disease detection, risk satisfaction and clinical decision-making,thereby improving patient outcomes. Recent studies demonstrate high diagnostic accuracy of AI models (AUC up to 0.99), highlighting their clinical potential. However, challenges such as data quality, interpretability, and regulatory concerns must be addressed for widespread implementation.*

Promise in identifying high-risk cardiovascular patients, enabling proactive, personalized, and preventive healthcare. Future research should focus on improving device accuracy, integrating multimodal data, and validating predictive algorithms in large-scale clinical Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, necessitating early identification of high-risk patients to improve clinical outcomes. Recent advancements in wearable technologies and remote monitoring systems have transformed cardiovascular care by enabling continuous, real-time health surveillance outside traditional clinical settings. Wearable devices such as smartwatches, electrocardiogram (ECG) patches, and biosensors can monitor key physiological parameters including heart rate, rhythm, physical activity, blood pressure, and oxygen saturation. These data streams, when integrated with remote monitoring platforms and advanced analytics, facilitate early detection of arrhythmias, ischemic changes, heart failure decompensation, and other cardiovascular abnormalities.

Moreover, the incorporation of artificial intelligence and machine learning algorithms enhances risk stratification by identifying subtle patterns and predicting adverse cardiovascular events before clinical manifestation. Remote patient monitoring improves patient engagement, adherence to therapy, and enables timely medical interventions, thereby reducing hospital readmissions and healthcare costs. However, challenges such as data accuracy, privacy concerns, interoperability, and regulatory issues must be addressed to optimize widespread implementation. In conclusion, wearable and remote monitoring technologies hold significant trials.

Keywords: Artificial intelligence, cardiovascular diseases, machine learning, deep learning, ECG, diagnosis, telemedicine

IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429 Volume 6, Issue 20, April 2026 Impact Factor: 8.2

I. INTRODUCTION

The heart is one of the most vital organs in the human body, ranking second in importance after the brain. Any dysfunction of the heart ultimately leads to systemic disorders throughout the body. We are living in modern era in which the surrounding world is undergoing significant changes that directly affect our daily lives. Cardiovascular diseases,which claims worldwide, remain among the five most dangerous diseases and occupy a leading position among global causes of mortality.

Common CVDs such as ischemic heart disease, heart failure, arrhythmias, and stroke often have silent or episodic presentations, making early detection difficult using traditional healthcare models.

Conventional cardiovascular monitoring relies heavily on intermittent hospital-based assessments, which may fail to capture transient abnormalities or early deterioration. In recent years, advances in wearable devices and remote patient monitoring (RPM) have transformed cardiovascular care by enabling continuous, real-time, and non-invasive monitoring of physiological parameters.

Wearable technologies—including smartwatches, ECG patches, and biosensors—allow monitoring of vital signs such as heart rate, electrocardiogram (ECG), oxygen saturation, and physical activity during daily life. When combined with telemedicine and cloud-based systems, these devices enable clinicians to remotely track patient health, identify early warning signs, and intervene promptly.

Furthermore, the integration of artificial intelligence (AI) and machine learning enhances predictive capabilities by identifying subtle physiological changes associated with adverse cardiovascular events.

Artificial Intelligence (AI), a branch of computer science that enables machines to mimic human intelligence, has emerged as a transformative tool in modern healthcare. AI encompasses technologies such as machine learning (ML), deep learning (DL), and natural language processing (NLP), which can analyze vast datasets, identify patterns, and make predictive decisions with high accuracy.

Artificial Intelligence (AI), a branch of computer science that enables machines to mimic human intelligence, has emerged as a transformative tool in modern healthcare. AI encompasses technologies such as machine learning (ML), deep learning (DL), and natural language processing (NLP), which can analyze vast datasets, identify patterns, and make predictive decisions with high accuracy.

In the field of cardiology, AI is increasingly being integrated into clinical practice to enhance the detection, diagnosis, and treatment of cardiovascular diseases. AI algorithms can process diverse data sources, including electrocardiograms (ECGs), medical imaging (such as echocardiography, CT, and MRI), electronic health records (EHRs), and wearable device data. This enables clinicians to detect abnormalities at an earlier stage, improve diagnostic precision, and personalize treatment strategies. Artificial intelligence (AI) refers to computational techniques that stimulate human intelligence to perform tasks such as learning,reasoning and decision-making. AI technologies,particularly machine learning (ML) and deep learning (DL),have shown great potential in transforming cardiovascular healthcare by improving accuracy, efficiency and personalization of care. Cardiovascular diseases (CVDs), including coronary artery disease,heart failure,arrhythmias and valvular heart diseaseare responsible for a significsnt proportion of global deaths.Traditional diagnostic and treatement methods often rely on clinician expertise and may be limited by variability and delayed detection. Numerous safe and efficient treatments are already available to combat CVD, which ranks high among public health priorities [5-8]. Over the last several years, AI's impact on CVD has been steadily increasing. The study of how computers and machine learning (ML) systems may mimic human intelligence via the use of computational techniques is known as artificial intellect. This area aims to solve human problems. A more cohesive, trustworthy, and efficient method of providing high-quality healthcare has been encouraged by the advent of artificial intelligence (AI), which provides methods for computers to mimic human cognitive functions such as learning and reasoning . Research into the early detection and prevention of cardiovascular disorders is now underway, building on the well-established practice of using AI in cardiovascular sciences. AI consists of complex analytical tools built into computers in an effort to imitate human intelligence. ML is an AI subfield that distinguishes itself from classical mathematical algorithms by including a “learning” component gleaned from massive datasets. There has been a lot of buzz about how CVD and AI may work together to revolutionize cardiovascular health diagnostics, prognoses, and treatments. The rapid detection and diagnosis of CVDs, together with the prediction of outcomes and evaluation of prognosis, may be greatly assisted by AI. Health records and other medical equipment are good places to start when looking for real-world data on patients' conditions and the healthcare system as a whole.

Types of AI used in cardiology -

Machine learning in cardiology - Numerous safe and efficient treatments are already available to combat CVD, which ranks high among public health priorities . Over the last several years, AI's impact on CVD has been steadily increasing. The study of how computers and machine learning (ML) systems may mimic human intelligence via the use of computational techniques is known as artificial intellect. This area aims to solve human problems. A more cohesive, trustworthy, and efficient method of providing high-quality healthcare has been encouraged by the advent of artificial intelligence (AI), which provides methods for computers to mimic human cognitive functions such as learning and reasoning . Research into the early detection and prevention of cardiovascular disorders is now underway, building on the well-established practice of using AI in cardiovascular sciences. AI consists of complex analytical tools built into computers in an effort to imitate human intelligence. ML is an AI subfield that distinguishes itself from classical mathematical algorithms by including a "learning" component gleaned from massive datasets. There has been a lot of buzz about how CVD and AI may work together to revolutionize cardiovascular health diagnostics, prognoses, and treatments. The rapid detection and diagnosis of CVDs, together with the prediction of outcomes and evaluation of prognosis, may be greatly assisted by AI.

Deep learning in cardiology - Deep Learning (DL) is an advanced subset of artificial intelligence and machine learning that utilizes multi-layered artificial neural networks to automatically learn hierarchical representations from large and complex datasets. Inspired by the structure and function of the human brain, deep learning models are capable of extracting intricate patterns from raw data without the need for extensive manual feature engineering. In cardiology, DL has gained significant attention due to its superior performance in analyzing high-dimensional data such as medical images, electrocardiograms (ECGs), and continuous physiological signals.The increasing availability of big data from electronic health records (EHRs), wearable devices, imaging modalities, and genomic studies has further accelerated the adoption of deep learning techniques in cardiovascular medicine.

Natural language processing (NLP) - Natural Language Processing (NLP) is a specialized domain of artificial intelligence that focuses on enabling computers to understand, interpret, analyze, and generate human language in both written and spoken forms. In cardiology, NLP plays a crucial role in extracting meaningful clinical insights from unstructured textual data, such as physician notes, discharge summaries, radiology reports, and electronic health records (EHRs).

Natural language learning- A substantial proportion of healthcare data—estimated to be over 70%—exists in unstructured text format. Traditional data analysis methods cannot effectively utilize this information. NLP bridges this gap by converting free-text clinical narratives into structured, analyzable data, thereby enhancing clinical decision-making, research, and healthcare delivery in cardiovascular medicine.

Computer vision - Clinical decision-making, research, and healthcare delivery in cardiovascular medicine. Natural Language Processing (NLP) is a specialized domain of artificial intelligence that focuses on enabling computers to understand, interpret, analyze, and generate human language in both written and spoken forms. In cardiology, NLP plays a crucial role in extracting meaningful clinical insights from unstructured textual data, such as physician notes, discharge summaries, radiology reports, and electronic health records (EHRs).

A substantial proportion of healthcare data—estimated to be over 70%—exists in unstructured text format. Traditional data analysis methods cannot effectively utilize this information. NLP bridges this gap by converting free-text clinical narratives into structured, analyzable data, thereby enhancing

AI in detection of cardiovascular diseases -

Due to their potentially fatal nature, cardiovascular diseases need the development of efficient solutions that allow early diagnosis and, ideally, prediction of their onset. The predictive power of modern technologies could help reduce the global prevalence of CVDs. Traditional methods for diagnosing these diseases include electrocardiogram, echocardiography, coronary angiography, stress testing, magnetic resonance imaging, or intracoronary ultrasonography. However, new technologies are improving health services and facilitating the detection of cardiovascular disease, particularly information and communication technologies (ICTs) and the development of artificial intelligence (AI) and its derivatives . Early and accurate detection is crucial to reduce morbidity and mortality. Artificial Intelligence (AI), particularly machine learning (ML) and deep learning (DL**)**, has emerged as a transformative tool for improving detection, risk stratification, and clinical decision-making in cardiology. DL uses neural networks for analyzing complex, high-dimensional data like images and signals. Natural language processing extracts useful information from unstructured clinical data. Their applications are mining electronic health records, identified undiagnosed cardiovascular conditions and extracting symptoms, risk factors and clinical notes. Advanced deep learning methods have greatly improved hoe diseases are detected. These methods help doctors make more accurate diagnosis. This chapter explains techniques like multiscale convulation , attention mechanisms, transfer learning and self supervised learning used in heathcare. Electrocardiography remains one of the most widely used diagnostic tools in cardiology. AI enhances ECG interpretation by utilizing deep learning models, particularly convolutional neural networks (CNNs) and recurrent neural networks (RNNs), to analyze waveform patterns.These systems are capable of detecting a wide range of cardiovascular abnormalities, including arrhythmias, atrial fibrillation, myocardial infarction, and conduction disorders. Unlike traditional methods, AI algorithms can identify subtle changes in ECG signals that may not be visible to the human eye. Furthermore, integration with wearable devices enables continuous and real-time monitoring, facilitating early detection of asymptomatic conditions and reducing the risk of sudden cardiac events. In echocardiography, AI-driven tools automate image interpretation, allowing precise assessement of cardiac structure and function, including ejection fraction(EF) and valvular abnormalities. Similarly, AI applications in cardiac imaging modalaities such as computed tomography(CT) and magnetic resonance imaging(MRI) facilitate the detection of coronary artery disease, plaque characterization and myocardial dysfunction with improved accuracy. Deep learning models, particularly convolutional neural networks(CNNs), play a central role in analyzing complex imaging and signal data, enabling automated and high-throughput diagnosis. Wearable AI-enabled devices further contribute to continuous cardiovascular monitoring, supporting early detection of arrhythmias such as atrial fibrillation in real-world settings. Overall, AI detection tools offer improved diagnostic accuracy, early disease identification and personalized risk assessement, thereby transforming cardiovascular events, enabling preventive interventions.

AI in diagnosis of cardiovascular diseases -

Artificial Intelligence (AI) has become an integral component in the modern diagnostic landscape of cardiovascular diseases (CVDs), offering advanced analytical capabilities that surpass conventional diagnostic approaches. By utilizing sophisticated computational techniques such as machine learning and deep learning, AI systems are capable of processing vast and complex healthcare datasets to identify subtle patterns and correlations that are often undetectable through traditional clinical methods. This has significantly enhanced the accuracy, efficiency, and timeliness of cardiovascular diagnosis.One of the primary contributions of AI lies in its ability to facilitate early detection and risk prediction of cardiovascular conditions. AI-driven predictive models analyze a combination of clinical parameters, imaging data, and patient history to identify individuals at high risk of developing diseases such as coronary artery disease and heart failure, even before the onset of clinical symptoms. This predictive capability supports preventive cardiology and enables clinicians to implement timely interventions, thereby reducing disease burden and improving patient outcomes. AI based ECG analysis plays a crucial role in diagnosing arrhythmias, myocardial infraction and heart failure often identifying subtle patterns that may not be visible to clinicians. In addition, AI-enhanced echocardiography provides automated and reproducible assessement of cardiac structure and function improving the detection of conditons such as cardiomyopathies and valvular heart disesases.

Risk stratification refers to the classification of patients into different risk categories (low, moderate, high) for developing cardiovascular events such as myocardial infarction, stroke, or heart failure. AI enhances this process by analyzing complex, multidimensional clinical data that traditional models may not fully capture. Biomarkers play a crucial role in the early detection, diagnosis, prognosis, and therapeutic monitoring of cardiovascular diseases (CVDs). Traditionally, clinicians interpret biomarkers alongside clinical data such as patient history, imaging findings, and laboratory results. However, the increasing volume and complexity of healthcare data make it challenging to extract meaningful insights using conventional approaches.Artificial Intelligence (AI) addresses this limitation by integrating heterogeneous data sources and identifying hidden patterns, thereby improving diagnostic accuracy and clinical decision-making. Cardiac biomarkers are indispensable in modern cardiology, providing critical insights into myocardial injury, stress, inflammation, and prognosis. Advances in biomarker research, along with integration into AI-based systems, are expected to further improve early diagnosis and personalized management of cardiovascular diseases. Wearsable devices combined with AI-driven remote monitoring are reshaping how cardiovascular diseases are detected, tracked and managed outside hospital settings. They enable continuous, real-time physiological data collection, allowing earlier diagnosis and timely intervention.

AI in treatement of cardiovascular diseases-

AI enhances cardiovascular treatment by enabling precision medicine, improving clinical decisions, supporting advanced interventions, and enabling continuous patient monitoring, ultimately leading to better outcomes and reduced mortality. AI combines multiple patient-specific data- Clinical data(age, BP, comorbidities), laboratory values(lipids,cardiac biomarkers),imaging(echography, angiography), genetic information. This creates a comprehensive patient profile for accurate treatment planning. AI helps choose the most suitable drug for cardiovascular patients by analyzing clinical data, comorbidities, and sometimes genetic factors. It predicts drug response, reduces adverse effects, and considers drug interactions, ensuring safer and more effective therapy. AI predicts how a patient will respond to a specific cardiovascular drug by analyzing clinical data, lab results, and sometimes genetic information. It helps identify responders and non-responders, enabling selection of the most effective therapy early. AI also significantly contributes to risk stratification and clinical decision support. It can predict the likelihood of adverse cardiovascular events such as myocardial infarction, stroke, and heart failure progression. These predictive capabilities assist healthcare professionals in identifying high-risk patients and implementing timely and appropriate therapeutic interventions. AI also significantly contributes to risk stratification and clinical decision support. It can predict the likelihood of adverse cardiovascular events such as myocardial infarction, stroke, and heart failure progression. These predictive capabilities assist healthcare professionals in identifying high-risk patients and implementing timely and appropriate therapeutic interventions. AI also significantly contributes to risk stratification and clinical decision support. It can predict the likelihood of adverse cardiovascular events such as myocardial infarction, stroke, and heart failure progression. These predictive capabilities assist healthcare professionals in identifying high-risk patients and implementing timely and appropriate therapeutic interventions. AI also significantly contributes to risk stratification and clinical decision support. It can predict the likelihood of adverse cardiovascular events such as myocardial infarction, stroke, and heart failure progression. These predictive capabilities assist healthcare professionals in identifying high-risk patients and implementing timely and appropriate therapeutic interventions.

Another important application of AI is in the optimization of pharmacotherapy. AI systems can evaluate drug interactions, suggest optimal drug combinations, and minimize adverse drug reactions. This enhances rational drug use

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 20, April 2026 Impact Factor: 8.2

and improves treatment outcomes, particularly in complex conditions such as acute coronary syndrome and chronic heart failure.

II. CONCLUSION

In the identification, diagnosis, and treatment of cardiovascular diseases (CVDs), artificial intelligence (AI) has become a potent and revolutionary tool. AI makes it possible to analyze big and complicated healthcare data with high accuracy and efficiency by combining cutting-edge technologies like computer vision, machine learning, deep learning, and natural language processing. It addresses the shortcomings of conventional cardiovascular care systems by greatly increasing early disease detection, improving diagnostic accuracy, and supporting individualized treatment plans.Real-time evaluation and early detection of cardiovascular issues are made easier by AI-driven technologies such as wearable-based monitoring devices, cardiac imaging, and ECG analysis. These technologies support proactive and preventative healthcare practices in addition to enhancing risk classification and clinical decision-making. By optimizing medication administration, forecasting treatment responses, and directing interventional procedures, artificial intelligence (AI) advances precision medicine in treatment, ultimately improving clinical outcomes and lowering mortality.The extensive application of AI in cardiovascular care is hampered by problems including data quality, interpretability, ethical concerns, and legal constraints, despite its tremendous potential. Further extensive validation, standardization, and integration into clinical workflows are therefore crucial.

In conclusion, by facilitating early detection, precise diagnosis, and individualized therapy, AI has the potential to completely transform cardiovascular healthcare and open the door to a more effective, patient-centered, and outcome-driven healthcare system. Future efforts to lower the worldwide burden of cardiovascular illnesses will be greatly aided by ongoing developments and the responsible application of AI technologies.

REFERENCES

[1]. Johnson KW, Torres Soto J, Glicksberg BS, et al. Artificial intelligence in cardiology. J Am Coll Cardiol. 2018;71:2668–2679.
[2]. .Topol EJ. High-performance medicine: convergence of human and AI. Nat Med. 2019;25:44–56.
[3]. Krittanawong C, Zhang H, Wang Z, et al. AI in precision cardiovascular medicine. J Am Coll Cardiol. 2017;69:2657–2664.
[4]. Dilsizian V, Siegel EL. AI in cardiac imaging. J Nucl Cardiol. 2014;21:743–749.
[5]. Attia ZI, Noseworthy PA, Lopez-Jimenez F, et al. AI-enabled ECG for AF detection. Lancet. 2019;394:861–867.
[6]. Hannun AY, Rajpurkar P, Haghpanahi M, et al. Arrhythmia detection using deep learning. Nat Med. 2019;25:65–69.
[7]. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380:1347–1358.
[8]. Obermeyer Z, Emanuel EJ. Predicting future using AI. N Engl J Med. 2016;375:1216–1219.
[9]. He J, Baxter SL, Xu J, et al. AI in healthcare implementation. Nat Med. 2019;25:30–36.
[10]. Kwon JM, Kim KH, Jeon KH, et al. AI predicting cardiac arrest. Resuscitation. 2018;130:91–9
[11]. Esteva A, Kuprel B, Novoa RA, et al. Deep learning in medical diagnosis. Nature. 2017;542:115–118.
[12]. Poplin R, Varadarajan AV, Blumer K, et al. Predicting CV risk from retinal images. Nat Biomed Eng. 2018;2:158–164.
[13]. Arbabshirani MR, et al. Advanced ML in cardiac CT. J Am Coll Radiol. 2017;14:165–172.
[14]. Zhang J, Gajjala S, Agrawal P, et al. Echo AI interpretation. Circulation. 2018;138:1623–1635.
[15]. Ouyang D, He B, Ghorbani A, et al. AI echocardiography analysis. Nature. 2020;580:252–256.
[16]. Shah SJ, Kitzman DW, Borlaug BA, et al. HF phenotype treatment. Circulation. 2016;134:73–90.
[17]. Mortazavi BJ, et al. AI predicting HF outcomes. Circ Cardiovasc Qual Outcomes. 2016;9:629–640.
[18]. Komorowski M, et al. AI clinical decision support. Nat Med. 2018;24:1716–1720.

ISSN: 2581-9429
Volume 6, Issue 20, April 2026
Impact Factor: 8.2

[19]. Sidey-Gibbons JAM, Sidey-Gibbons CJ. ML in clinical medicine. BMC Med Res Methodol. 2019;19:64.
[20]. Beam AL, Kohane IS. Big data & ML in healthcare. JAMA. 2018;319:1317–1318.
[21]. Litjens G, et al. DL in medical imaging. Med Image Anal. 2017;42:60–88.
[22]. Narula S, et al. AI in cardiovascular imaging. J Am Coll Cardiol. 2016;68:1657–1670.
[23]. Al'Aref SJ, et al. AI coronary CT angiography. JACC Cardiovasc Imaging. 2019;12:1973–1984.
[24]. Dey D, et al. ML for coronary artery disease. JACC. 2018;72:307–309.
[25]. [12:48, 5/2/2026] : Steinhubl SR, et al. Digital medicine for CV disease. JAMA. 2015;313:131–132.
[26]. Tison GH, et al. Smartphone AF detection. Lancet Digit Health. 2018;1:e66–e75.
[27]. Perez MV, et al. Apple Heart Study. N Engl J Med. 2019;381:1909–1917.
[28]. [12:49, 5/2/2026] : Weng SF, et al. ML for CVD risk prediction. PLoS One. 2017;12:e0174944.
[29]. Khera R, et al. AI risk prediction models. JAMA Cardiol. 2019;4:1189–1195.
[30]. Ambale-Venkatesh B, et al. ML prediction of outcomes. Circulation. 2017;136:1921–1930.
[31]. Doshi-Velez F, Kim B. Interpretable ML. arXiv. 2017.
[32]. Libby P. Atherosclerosis update. Nature. 2021;592:524–533.
[33]. World Health Organization. Cardiovascular diseases report. WHO; 2021.
[34]. Deo RC. ML in medicine. Circulation. 2015;132:1920–1930.
[35]. Shameer K, et al. AI in cardiology. Trends Cardiovasc Med. 2018;28:329–337.
[36]. Sengupta PP, et al. Cognitive ML in cardiology. JACC. 2016;68:1597–1607.
[37]. Hashimoto DA, et al. AI in surgery & medicine. Ann Surg. 2018;268:70–76.
[38]. Patel BN, et al. Human–AI interaction. Lancet Digit Health. 2019;1:e5–e6.
[39]. Gulshan V, et al. AI diagnostic systems. JAMA. 2016;316:2402–2410.
[40]. Miotto R, et al. Deep patient model. Sci Rep. 2016;6:26094.
[41]. Choi E, et al. Predictive healthcare ML. MLHC. 2016.
[42]. Yu KH, et al. AI in healthcare review. Nat Biomed Eng. 2018;2:719–731.
[43]. Obermeyer Z, Mullainathan S. Bias in AI healthcare. Science. 2019;366:447–453.
[44]. Sendak MP, et al. ML clinical adoption. NPJ Digit Med. 2020;3:17.
[45]. Ting DSW, et al. AI medical imaging. Lancet. 2017;390:2211–2223.
[46]. Kermany DS, et al. DL medical diagnosis. Cell. 2018;172:1122–1131.
[47]. Rumsfeld JS, et al. Big data cardiology. Circulation. 2016;134:1392–1405.
[48]. Benjamin EJ, et al. Heart disease statistics. Circulation. 2019;139:e56–e528.
[49]. Goldberger JJ, et al. Risk prediction models. Circulation. 2019;140:164–177.
[50]. Attia ZI, et al. AI ECG HF detection. Nat Med. 2019;25:70–74.
[51]. Ribeiro AH, et al. ECG DL diagnosis. Nat Commun. 2020;11:1760.
[52]. Ghorbani A, et al. DL echo interpretation. NPJ Digit Med. 2020;3:1–10.